ASCO 2026, taking place May 29–June 2 at McCormick Place in Chicago, Illinois, with online access, is expected to deliver practice-relevant updates across a broad range of malignancies. This year’s program includes studies focused on precision oncology, PARP inhibitor combinations, liquid biopsy–guided treatment strategies, computational pathology, antibody–drug conjugates, treatment de-escalation approaches, and biomarker-driven therapy selection in both metastatic hormone-sensitive and castration-resistant disease settings.
This article highlights major prostate cancer (PC) trials and translational studies scheduled for presentation at ASCO 2026, including phase II and phase III studies with potential to influence future treatment strategies, patient selection, and personalized management approaches in advanced prostate cancer.
PROTRACT: ctDNA-Guided Therapy Versus Clinician’s Choice in mCRPC After Abiraterone
Abstract: 5017
Presenter: Corinne Maurice-Dror (Vancouver, Canada)
Trial Type: Phase II, Randomized
Session: Rapid Oral Abstract Session
ClinicalTrials.gov ID: NCT04015622
PROTRACT is a randomized, open-label phase II trial comparing ctDNA-guided treatment selection versus clinician’s choice of therapy in patients with metastatic castration-resistant prostate cancer progressing after abiraterone plus prednisone.
The biomarker-directed strategy uses circulating tumor DNA fraction as a predictive biomarker: patients with ctDNA fraction <2% receive enzalutamide, while patients with ctDNA fraction ≥2% receive docetaxel. The comparator arm consists of clinician’s choice of enzalutamide or docetaxel. At disease progression, patients cross over to the alternate therapy.
The primary endpoint of the study is progression-free survival on first-line therapy. Secondary endpoints include objective response, PSA response, second progression-free survival, overall survival, and correlation of ctDNA-based genomic alterations with treatment response.
At ASCO 2026, PROTRACT may help clarify the role of ctDNA-guided treatment selection after abiraterone progression in mCRPC.
COMPPARE: Prospective Comparison of Proton Versus Photon Radiation in PC
Abstract: LBA5012
Presenter: Nancy P. Mendenhall (Jacksonville, United States)
Trial Type: Prospective Comparative Study
Session: Rapid Oral Abstract Session
COMPPARE is a large, prospective, pragmatic, controlled study comparing patient-centric outcomes between proton therapy and photon-based intensity-modulated radiation therapy in patients with localized prostate cancer.
The study evaluates quality of life, toxicity, and disease control outcomes between the two radiation approaches. In addition, the study includes prespecified subgroup analyses according to race, comorbidity, age, fractionation schedule, and prostate cancer risk group.
At ASCO 2026, COMPPARE may provide important comparative data on proton versus photon radiation therapy in localized PC.
Read more about Radiotherapy for Prostate Cancer on OncoDaily.
YL201: Phase II Study of an Anti-B7H3 Antibody–Drug Conjugate in Previously Treated mCRPC
Abstract: 5015
Presenter: Dingwei Ye (Shanghai, China)
Trial Type: Phase II
Session: Rapid Oral Abstract Session
ClinicalTrials.gov ID: NCT06241846
This phase II multicenter study evaluates YL201, an anti-B7H3 antibody–drug conjugate, in patients with metastatic castration-resistant prostate cancer previously treated with novel hormonal therapy and up to two prior chemotherapy lines.
B7H3 is an immune regulatory protein highly expressed in several solid tumors, including advanced prostate cancer, making it an emerging therapeutic target in mCRPC. YL201 is an antibody–drug conjugate designed to selectively deliver a cytotoxic payload to B7H3-expressing tumor cells. The study evaluates the efficacy, safety, and pharmacokinetic characteristics of YL201. Primary endpoints include objective response rate and radiographic progression-free survival according to RECIST 1.1 and PCWG3 criteria.
At ASCO 2026, this study may further define the potential role of B7H3-targeted ADC therapy in previously treated mCRPC.
A-DREAM (Alliance A032101): ADT Interruption in Exceptional Responders with mHSPC
Abstract: 5004
Presenter: Atish Dipankar Choudhury (Boston, United States)
Trial Type: Phase II, Single-Arm, Open-Label
Session: Oral Abstract Session
ClinicalTrials.gov ID: NCT05241860
A-DREAM (Alliance A032101) is a phase II trial evaluating interruption of androgen deprivation therapy and androgen receptor pathway inhibitor therapy in patients with mHSPC who demonstrate exceptional responses to treatment. The study explores whether selected patients with deep and sustained responses to intensive hormonal therapy may safely undergo treatment interruption strategies, with the goal of allowing testosterone recovery while maintaining disease control.
The primary objective is to determine the proportion of patients who achieve an 18-month treatment-free interval with recovery of eugonadal testosterone levels after therapy interruption.
At ASCO 2026, A-DREAM may provide insight into treatment interruption strategies in exceptionally responding mHSPC.
ENZAMET: Decipher Genomic Classifier and Benefit from Adding Docetaxel to ADT Plus Enzalutamide
Abstract: 5001
Presenter: Christopher Sweeney (Adelaide, Australia)
Trial Type: Biomarker Analysis of a Phase III Trial
Session: Oral Abstract Session
This analysis from the ENZAMET study evaluates whether a Decipher Prostate Genomic Classifier score >0.85 can identify patients with metastatic hormone-sensitive prostate cancer who derive benefit associated with concurrent docetaxel use alongside androgen deprivation therapy plus enzalutamide.
ENZAMET was an international, open-label, randomized phase III trial evaluating enzalutamide plus androgen deprivation therapy versus standard non-steroidal antiandrogen therapy plus androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer. Concurrent docetaxel use was permitted. The Decipher Prostate Genomic Classifier is a genomic risk stratification tool designed to help identify aggressive disease biology and guide treatment intensification strategies in prostate cancer.
At ASCO 2026, this analysis may help refine biomarker-guided treatment intensification strategies in mHSPC.
CHAMP: Chemoimmunotherapy for Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
Abstract: 5016
Presenter: Andrew J. Armstrong (Durham, United States)
Trial Type: Phase II, Single-Arm, Open-Label, Multicenter
Session: Rapid Oral Abstract Session
ClinicalTrials.gov ID: NCT04709276
CHAMP is a phase II trial evaluating a chemoimmunotherapy combination of nivolumab, ipilimumab, carboplatin, and cabazitaxel in patients with neuroendocrine or aggressive variant metastatic PC. Neuroendocrine and aggressive variant prostate cancers are biologically aggressive subtypes associated with poor prognosis, rapid progression, visceral metastases, lineage plasticity, and resistance to conventional androgen receptor–directed therapies.
The study evaluates the safety and efficacy of combined dual immune checkpoint blockade and platinum-taxane chemotherapy in this high-risk population. The primary endpoint is progression-free survival at 6 months based on immune-modified PCWG3/RECIST 1.1 criteria.
At ASCO 2026, CHAMP may further define the role of chemoimmunotherapy approaches in neuroendocrine or aggressive variant metastatic PC.
Read more about Opdivo (Nivolumab) on OncoDaily.
CHAARTED (E3805): Spatial Transcriptomics–Guided Model to Stratify Docetaxel Benefit in mHSPC
Abstract: 5002
Presenter: Sebastian R. Medina (Sydney, Australia)
Trial Type: Translational Analysis of a Phase III Trial
Session: Oral Abstract Session
ClinicalTrials.gov ID: NCT00309985
This translational analysis from the CHAARTED trial (ECOG-ACRIN E3805) evaluates a spatial transcriptomics–guided computational pathology model to stratify benefit from docetaxel in mHSPC.
The trial was a randomized phase III trial comparing androgen-deprivation therapy plus docetaxel versus androgen-deprivation therapy alone in patients with metastatic hormone-sensitive prostate cancer. The trial enrolled 790 patients and evaluated whether early docetaxel improved overall survival.
At ASCO 2026, this analysis may provide insight into spatial transcriptomics–guided treatment stratification in mHSPC.
TALAPRO-3: Talazoparib Plus Enzalutamide in HRR-Altered mCSPC
Abstract: LBA5007
Presenter: Neeraj Agarwal (Salt Lake City, United States)
Trial Type: Phase III, Randomized
Session: Oral Abstract Session
ClinicalTrials.gov ID: NCT04821622
TALAPRO-3 is a phase III trial evaluating talazoparib plus enzalutamide versus placebo plus enzalutamide in patients with metastatic castration-sensitive prostate cancer harboring homologous recombination repair gene alterations. Ongoing androgen deprivation therapy is maintained in both treatment arms.
Talazoparib is a PARP inhibitor designed to exploit defects in DNA damage repair pathways, while enzalutamide is an androgen receptor pathway inhibitor widely used in advanced prostate cancer. The study evaluates whether combining PARP inhibition with androgen receptor blockade can improve outcomes in biomarker-selected mCSPC. The primary endpoint of the study is radiographic progression-free survival.
At ASCO 2026, TALAPRO-3 may help clarify the role of PARP inhibitor–based combinations in HRR-altered mCSPC.
FUZUPRO: Fuzuloparib Plus Abiraterone as First-Line Treatment for mCRPC
Abstract: 5008
Presenter: Dingwei Ye (Shanghai, China)
Trial Type: Phase III, Randomized, Double-Blind, Placebo-Controlled
Session: Oral Abstract Session
ClinicalTrials.gov ID: NCT04691804
FUZUPRO is a phase III trial evaluating fuzuloparib combined with abiraterone acetate plus prednisone versus placebo plus abiraterone acetate plus prednisone as first-line treatment for mCRPC.
Fuzuloparib is a PARP inhibitor designed to exploit defects in DNA damage repair pathways, while abiraterone is a standard androgen biosynthesis inhibitor used in mCRPC. The study evaluates whether combining PARP inhibition with androgen receptor pathway blockade can improve radiographic progression-free survival in both unselected patients and those harboring DNA damage repair deficiency.
The primary endpoint of the study is radiographic progression-free survival assessed by blinded independent central review using RECIST 1.1 and PCWG3 criteria.
At ASCO 2026, FUZUPRO may further define PARP inhibitor combination strategies in first-line mCRPC.
ZZFIRST: Enzalutamide Plus Talazoparib in Metastatic Hormone-Naïve Prostate Cancer
Abstract: 5006
Presenter: Joaquin Mateo (Barcelona, Spain)
Trial Type: Phase II, Randomized
Session: Oral Abstract Session
ClinicalTrials.gov ID: NCT04332744
ZZFIRST is a randomized phase II trial evaluating enzalutamide with or without talazoparib, in addition to androgen deprivation therapy, in patients with high-volume metastatic hormone-naïve prostate cancer.
Talazoparib is a PARP inhibitor designed to exploit defects in homologous recombination repair pathways, while enzalutamide is a potent androgen receptor pathway inhibitor widely used in advanced prostate cancer. The study explores whether combining PARP inhibition with androgen receptor blockade earlier in the disease course can improve outcomes in mHNPC.
The primary endpoint of the study is PSA complete response (PSA-CR).
At ASCO 2026, ZZFIRST may provide additional insight into PARP inhibitor combinations in metastatic hormone-naïve PC.
Find more information on official ASCO website.